Highly diverse efficacy of salvage treatment regimens for relapsed or refractory peripheral T-cell lymphoma

A systematic review

Ya Ting Yang, Cheng-Jeng Tai, Chieh-Feng Chen, Hong Cheng Wu, Natalia Mikhaylichenko, Hsien Tsai Chiu, Yun-Yi Chen, Yi-Hsin Hsu

Research output: Contribution to journalReview article

4 Citations (Scopus)

Abstract

Background The goal of this study was to perform a systematic review to examine the efficacy and safety of various salvage therapy regimens on patients with relapsed/refractory PTCL. Method The electronic searches were performed using PubMed, Cochrane Library, EMBASE, and Web of Science from inception through June 2015, with search terms related to relapsed/ refractory PTCL, salvage chemotherapy regimens, and clinical trials. An eligible study met the following inclusion criteria: (1) Patients had refractory or relapsed PTCL; (2) drug regimens were used for salvage therapy; (3) the study was a clinical trial; (4) the study reported on a series of at least 10 patients of PTCL. Results Of 35 records identified, a total of 14 studies were eligible for systematic reviews, and 12 different salvage regimens were investigated. A total of 618 relapsed/refractory PTCL patients were identified. The ORRs ranged from 22% for those treated with lenalidomide to 86% for those with brentuximab vedotin. By the three most frequent subtypes, the ORRs ranged from 14.2% to 71.5% for patients with the PTCL-NOS subtype, 8% to 54% for AITL subtypes, and 24% to 86% for the ALCL subtype. The medians of DOR, PFS, and OS ranged from 2.5 to 16.6 months, 2.6 to 13.3 months, and 3.6 to 14.5 months, respectively. The most frequently reported grade 3 or 4 adverse events (AEs) were hematological AEs, such as neutropenia and thrombocytopenia. Conclusion The efficacy of salvage therapy regimens is highly diverse for patients with relapsed/refractory PTCL; this heterogeneity in therapeutic effects might be due to the diversity in mechanisms, PTCL subtype distribution, and/or numbers/profiles of prior therapy. Comparative studies with matched pair analysis are warranted for more evidence of the salvage treatment effect on relapsed or heavily pretreated patients with PTCL.
Original languageEnglish
JournalPLoS One
Volume11
Issue number10
DOIs
Publication statusPublished - Oct 1 2016

Cite this

Highly diverse efficacy of salvage treatment regimens for relapsed or refractory peripheral T-cell lymphoma : A systematic review. / Yang, Ya Ting; Tai, Cheng-Jeng; Chen, Chieh-Feng; Wu, Hong Cheng; Mikhaylichenko, Natalia; Chiu, Hsien Tsai; Chen, Yun-Yi; Hsu, Yi-Hsin.

In: PLoS One, Vol. 11, No. 10, 01.10.2016.

Research output: Contribution to journalReview article

@article{0705c841a0af472d84251267b5e3b35a,
title = "Highly diverse efficacy of salvage treatment regimens for relapsed or refractory peripheral T-cell lymphoma: A systematic review",
abstract = "Background The goal of this study was to perform a systematic review to examine the efficacy and safety of various salvage therapy regimens on patients with relapsed/refractory PTCL. Method The electronic searches were performed using PubMed, Cochrane Library, EMBASE, and Web of Science from inception through June 2015, with search terms related to relapsed/ refractory PTCL, salvage chemotherapy regimens, and clinical trials. An eligible study met the following inclusion criteria: (1) Patients had refractory or relapsed PTCL; (2) drug regimens were used for salvage therapy; (3) the study was a clinical trial; (4) the study reported on a series of at least 10 patients of PTCL. Results Of 35 records identified, a total of 14 studies were eligible for systematic reviews, and 12 different salvage regimens were investigated. A total of 618 relapsed/refractory PTCL patients were identified. The ORRs ranged from 22{\%} for those treated with lenalidomide to 86{\%} for those with brentuximab vedotin. By the three most frequent subtypes, the ORRs ranged from 14.2{\%} to 71.5{\%} for patients with the PTCL-NOS subtype, 8{\%} to 54{\%} for AITL subtypes, and 24{\%} to 86{\%} for the ALCL subtype. The medians of DOR, PFS, and OS ranged from 2.5 to 16.6 months, 2.6 to 13.3 months, and 3.6 to 14.5 months, respectively. The most frequently reported grade 3 or 4 adverse events (AEs) were hematological AEs, such as neutropenia and thrombocytopenia. Conclusion The efficacy of salvage therapy regimens is highly diverse for patients with relapsed/refractory PTCL; this heterogeneity in therapeutic effects might be due to the diversity in mechanisms, PTCL subtype distribution, and/or numbers/profiles of prior therapy. Comparative studies with matched pair analysis are warranted for more evidence of the salvage treatment effect on relapsed or heavily pretreated patients with PTCL.",
author = "Yang, {Ya Ting} and Cheng-Jeng Tai and Chieh-Feng Chen and Wu, {Hong Cheng} and Natalia Mikhaylichenko and Chiu, {Hsien Tsai} and Yun-Yi Chen and Yi-Hsin Hsu",
year = "2016",
month = "10",
day = "1",
doi = "10.1371/journal.pone.0161811",
language = "English",
volume = "11",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "10",

}

TY - JOUR

T1 - Highly diverse efficacy of salvage treatment regimens for relapsed or refractory peripheral T-cell lymphoma

T2 - A systematic review

AU - Yang, Ya Ting

AU - Tai, Cheng-Jeng

AU - Chen, Chieh-Feng

AU - Wu, Hong Cheng

AU - Mikhaylichenko, Natalia

AU - Chiu, Hsien Tsai

AU - Chen, Yun-Yi

AU - Hsu, Yi-Hsin

PY - 2016/10/1

Y1 - 2016/10/1

N2 - Background The goal of this study was to perform a systematic review to examine the efficacy and safety of various salvage therapy regimens on patients with relapsed/refractory PTCL. Method The electronic searches were performed using PubMed, Cochrane Library, EMBASE, and Web of Science from inception through June 2015, with search terms related to relapsed/ refractory PTCL, salvage chemotherapy regimens, and clinical trials. An eligible study met the following inclusion criteria: (1) Patients had refractory or relapsed PTCL; (2) drug regimens were used for salvage therapy; (3) the study was a clinical trial; (4) the study reported on a series of at least 10 patients of PTCL. Results Of 35 records identified, a total of 14 studies were eligible for systematic reviews, and 12 different salvage regimens were investigated. A total of 618 relapsed/refractory PTCL patients were identified. The ORRs ranged from 22% for those treated with lenalidomide to 86% for those with brentuximab vedotin. By the three most frequent subtypes, the ORRs ranged from 14.2% to 71.5% for patients with the PTCL-NOS subtype, 8% to 54% for AITL subtypes, and 24% to 86% for the ALCL subtype. The medians of DOR, PFS, and OS ranged from 2.5 to 16.6 months, 2.6 to 13.3 months, and 3.6 to 14.5 months, respectively. The most frequently reported grade 3 or 4 adverse events (AEs) were hematological AEs, such as neutropenia and thrombocytopenia. Conclusion The efficacy of salvage therapy regimens is highly diverse for patients with relapsed/refractory PTCL; this heterogeneity in therapeutic effects might be due to the diversity in mechanisms, PTCL subtype distribution, and/or numbers/profiles of prior therapy. Comparative studies with matched pair analysis are warranted for more evidence of the salvage treatment effect on relapsed or heavily pretreated patients with PTCL.

AB - Background The goal of this study was to perform a systematic review to examine the efficacy and safety of various salvage therapy regimens on patients with relapsed/refractory PTCL. Method The electronic searches were performed using PubMed, Cochrane Library, EMBASE, and Web of Science from inception through June 2015, with search terms related to relapsed/ refractory PTCL, salvage chemotherapy regimens, and clinical trials. An eligible study met the following inclusion criteria: (1) Patients had refractory or relapsed PTCL; (2) drug regimens were used for salvage therapy; (3) the study was a clinical trial; (4) the study reported on a series of at least 10 patients of PTCL. Results Of 35 records identified, a total of 14 studies were eligible for systematic reviews, and 12 different salvage regimens were investigated. A total of 618 relapsed/refractory PTCL patients were identified. The ORRs ranged from 22% for those treated with lenalidomide to 86% for those with brentuximab vedotin. By the three most frequent subtypes, the ORRs ranged from 14.2% to 71.5% for patients with the PTCL-NOS subtype, 8% to 54% for AITL subtypes, and 24% to 86% for the ALCL subtype. The medians of DOR, PFS, and OS ranged from 2.5 to 16.6 months, 2.6 to 13.3 months, and 3.6 to 14.5 months, respectively. The most frequently reported grade 3 or 4 adverse events (AEs) were hematological AEs, such as neutropenia and thrombocytopenia. Conclusion The efficacy of salvage therapy regimens is highly diverse for patients with relapsed/refractory PTCL; this heterogeneity in therapeutic effects might be due to the diversity in mechanisms, PTCL subtype distribution, and/or numbers/profiles of prior therapy. Comparative studies with matched pair analysis are warranted for more evidence of the salvage treatment effect on relapsed or heavily pretreated patients with PTCL.

UR - http://www.scopus.com/inward/record.url?scp=84990964598&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84990964598&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0161811

DO - 10.1371/journal.pone.0161811

M3 - Review article

VL - 11

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 10

ER -